Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
BioMarin inks $275M Alesta buyout to challenge AstraZeneca
Alesta is developing a small molecule to treat hypophosphatasia, a rare bone disease that is targeted by AstraZeneca’s enzyme replacement therapy, Strensiq.
Nick Paul Taylor
Aug 18, 2026 9:15am
AstraZeneca ends phase 3 cancer trial as bispecific underwhelms
Aug 17, 2026 4:45am
Taiho and Cullinan secure lung cancer victory to challenge J&J
Aug 13, 2026 6:00am
Pathos AI pads pipeline with $2.2B Alphamab deal, AZ pact
Aug 4, 2026 7:36am
Fierce Pharma
Editor’s Corner: Why an AZ-BMS merger would be a very bad idea
Aug 3, 2026 12:25am
GSK unveils cost-saving plan to fund R&D, move research HQ
Jul 28, 2026 9:50am
